Get started
Author

Brandon Cieniewicz

Observed names: B. Cieniewicz, Cieniewicz, Brandon
ORCID: 0000-0003-3268-7444
Observed ORCID: 0000-0003-3268-7444
OpenAlex ID: A5045121804
Identification of preexisting adaptive immunity to Cas9 proteins in humans
2019 · Carsten T. Charlesworth, Priyanka S. Deshpande, et al. · Nature Medicine · 1,164
PDF
Alloantigen-specific type 1 regulatory T cells suppress through CTLA-4 and PD-1 pathways and persist long-term in patients
2021 · Pauline P. Chen, Alma-Martina Cepika, et al. · Science Translational Medicine · 71
RNA interference in marine and freshwater sponges: actin knockdown in Tethya wilhelma and Ephydatia muelleriby ingested dsRNA expressing bacteria
2011 · Ajna S Rivera, Jörg U Hammel, et al. · BMC Biotechnology · 65
PDF
The evolution and function of the Pax/ S ix regulatory network in sponges
2013 · A. Rivera, I. Winters, et al. · Evolution & Development · 37
Engineered type 1 regulatory T cells designed for clinical use kill primary pediatric acute myeloid leukemia cells
2020 · Brandon Cieniewicz, Molly Javier Uyeda, et al. · Haematologica · 23
PDF
Murine Gammaherpesvirus 68 Pathogenesis Is Independent of Caspase-1 and Caspase-11 in Mice and Impairs Interleukin-1β Production upon Extrinsic Stimulation in Culture
2015 · Brandon Cieniewicz, Qiwen Dong, et al. · Journal of Virology · 22
BHLHE40 Regulates IL-10 and IFN-γ Production in T Cells but Does Not Interfere With Human Type 1 Regulatory T Cell Differentiation
2021 · Molly Javier Uyeda, Robert A. Freeborn, et al. · Frontiers in Immunology · 21
PDF
Interplay of Murine Gammaherpesvirus 68 with NF-kappaB Signaling of the Host
2016 · Brandon Cieniewicz, Alexis L. Santana, et al. · Frontiers in Microbiology · 19
PDF
Pre-clinical development and molecular characterization of an engineered type 1 regulatory T-cell product suitable for immunotherapy
2021 · Jeffrey Mao-Hwa Liu, Ping Chen, et al. · Cytotherapy · 12
PDF
Chimeric TIM-4 receptor-modified T cells targeting phosphatidylserine mediates both cytotoxic anti-tumor responses and phagocytic uptake of tumor-associated antigen for T cell cross-presentation
2023 · Brandon Cieniewicz, Ankit Bhatta, et al. · Molecular Therapy · 11
PDF
IKKα-Mediated Noncanonical NF-κB Signaling Is Required To Support Murine Gammaherpesvirus 68 Latency In Vivo
2022 · Brandon Cieniewicz, Varvara Kirillov, et al. · Journal of Virology · 10
PDF
Enhanced Response of T Cells from Murine Gammaherpesvirus 68-Infected Mice Lacking the Suppressor of T Cell Receptor Signaling Molecules Sts-1 and Sts-2
2014 · Brandon Cieniewicz, Nicholas Carpino, et al. · PLoS ONE · 5
PDF
Therapeutic Targeting of TIM-4-L with Engineered T Cells for Acute Myeloid Leukemia
2024 · Brandon Cieniewicz, Edson Oliveira, et al. · Clinical Cancer Research · 3
PDF
First-in-human study of autologous chimeric engulfment receptor T-cell CER-1236 targeting TIM-4-l in acute myeloid leukemia (CertainT-1).
2025 · Abhishek Maiti, Jeremy L. Ramdial, et al. · Journal of Clinical Oncology · 1
PDF
Data from Therapeutic Targeting of TIM-4-L with Engineered T Cells for Acute Myeloid Leukemia
2024 · Brandon Cieniewicz, Edson Oliveira, et al. · 1
First-In-Human Clinical Experience with CER-1236, a First-In-Class TIM-4–Based Phagocytic CAR-T Therapy, Including Platelet Transfusion Independence In an Index Patient with High-Risk MDS/AML (inv(3)/Mecom)
2026 · Luke Mountjoy, Robert Sikorski, et al. · Transplantation and Cellular Therapy
202 CER-1236, an investigational T cell product targeting TIM-4 Ligand, exhibits sustained effector function and resistance to exhaustion
2025 · Ankit Bhatta, Bi Yu, et al. · Journal for ImmunoTherapy of Cancer
PDF
AML-795: First-in-Human Study of Autologous Chimeric Engulfment Receptor T Cell CER-1236 Targeting TIM-4-L in Acute Myeloid Leukemia (CertainT-1)
2025 · Abhishek Maiti, Jeremy Ramdial, et al. · Clinical Lymphoma Myeloma & Leukemia
POSTER: AML-795 First-in-Human Study of Autologous Chimeric Engulfment Receptor T Cell CER-1236 Targeting TIM-4-L in Acute Myeloid Leukemia (CertainT-1)
2025 · Abhishek Maiti, Jeremy Ramdial, et al. · Clinical Lymphoma Myeloma & Leukemia
363 TIM-4-L expression on ovarian cancer can be targeted by engineered chimeric engulfment receptor T cells without toxicity
2024 · Ankit Bhatta, Brandon Cieniewicz, et al. · Journal for ImmunoTherapy of Cancer
Supplementary Data 1 from Therapeutic Targeting of TIM-4-L with Engineered T Cells for Acute Myeloid Leukemia
2024 · Brandon Cieniewicz, Edson Oliveira, et al.
Data from Therapeutic Targeting of TIM-4-L with Engineered T Cells for Acute Myeloid Leukemia
2024 · Brandon Cieniewicz, Edson Oliveira, et al.
378 Chimeric engulfment receptor (CER) T cells with a TLR2 domain synergize with an EGFR inhibitor to target NSCLC cells in vitro and demonstrate APC-like function
2022 · Sunil Thomas, Harini Kethar, et al. · Journal for ImmunoTherapy of Cancer
PDF
207 Enhanced antigen capture, antigen-presenting cell (APC)-like function, and cytotoxic responses with chimeric engulfment receptor (CER) T cells
2021 · Daniel Corey, Sunil Thomas, et al. · Journal for ImmunoTherapy of Cancer
PDF
146 Alloantigen-specific Tr1 cells designed to prevent GvHD have a distinct molecular identity and suppress through CTLA-4 and PD-1
2020 · Alma-Martina Cepika, Pauline P Chen, et al. · Journal for ImmunoTherapy of Cancer
Works count: 27
Citation count: 1,465
H-index: 10
I10-index: 11
Year
Topic
Type